Inhibrx (INBX) Competitors $14.49 +0.02 (+0.14%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INBX vs. QURE, ETNB, PLRX, RLAY, AVXL, KROS, KURA, IMNM, TYRA, and ERASShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include uniQure (QURE), 89bio (ETNB), Pliant Therapeutics (PLRX), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Keros Therapeutics (KROS), Kura Oncology (KURA), Immunome (IMNM), Tyra Biosciences (TYRA), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. uniQure 89bio Pliant Therapeutics Relay Therapeutics Anavex Life Sciences Keros Therapeutics Kura Oncology Immunome Tyra Biosciences Erasca Inhibrx (NASDAQ:INBX) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations. Which has better valuation and earnings, INBX or QURE? Inhibrx has higher earnings, but lower revenue than uniQure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx$1.57M133.77-$154.96MN/AN/AuniQure$28.59M29.58-$308.48M-$4.96-3.50 Does the MarketBeat Community prefer INBX or QURE? uniQure received 622 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 70.67% of users gave uniQure an outperform vote while only 59.62% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformInhibrxOutperform Votes3159.62% Underperform Votes2140.38% uniQureOutperform Votes65370.67% Underperform Votes27129.33% Is INBX or QURE more profitable? Inhibrx has a net margin of 0.00% compared to uniQure's net margin of -837.80%. Inhibrx's return on equity of -113.74% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets InhibrxN/A -113.74% -80.56% uniQure -837.80%-188.82%-32.17% Does the media prefer INBX or QURE? In the previous week, uniQure had 3 more articles in the media than Inhibrx. MarketBeat recorded 5 mentions for uniQure and 2 mentions for Inhibrx. uniQure's average media sentiment score of 0.24 beat Inhibrx's score of 0.08 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate INBX or QURE? uniQure has a consensus target price of $33.88, suggesting a potential upside of 95.24%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00uniQure 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in INBX or QURE? 82.5% of Inhibrx shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 22.2% of Inhibrx shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryuniQure beats Inhibrx on 10 of the 16 factors compared between the two stocks. Ad DTIA brand new opportunity in the stock market revealedToday, I want to unlock a brand new opportunity in the stock market… One that has been able to pay out around 100% in 5 days or less so far on REAL money… It’s all thanks to a hidden force that drives some of the BIGGEST & most repetitive moves in stocks… I call it a Gamma Pocket…Will you be the next trader to discover the power of Gamma Pockets? Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$209.47M$2.96B$5.22B$9.27BDividend YieldN/A1.91%5.12%4.29%P/E RatioN/A45.6887.4217.27Price / Sales133.77417.621,166.39119.60Price / CashN/A174.7643.2337.83Price / BookN/A3.924.834.93Net Income-$154.96M-$42.00M$120.46M$225.34M7 Day Performance-0.41%-1.23%-0.26%1.13%1 Month Performance2.91%2.58%15.99%2.76%1 Year Performance-53.66%19.36%30.22%16.90% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx1.1944 of 5 stars$14.49+0.1%N/A-53.7%$209.47M$1.57M0.00166Gap DownQUREuniQure3.5816 of 5 stars$17.32+12.5%$32.13+85.5%+174.5%$844.23M$28.59M-3.36500Gap UpETNB89bio1.8468 of 5 stars$7.91+2.9%$30.33+283.5%-27.2%$839.46MN/A-2.6440PLRXPliant Therapeutics3.7605 of 5 stars$13.77+3.5%$40.50+194.1%-21.9%$837.90M$1.58M0.0090RLAYRelay Therapeutics2.301 of 5 stars$4.80+1.9%$20.50+327.1%-62.4%$803.42M$25.55M-1.80304AVXLAnavex Life Sciences3.6129 of 5 stars$9.23+9.1%$43.00+365.9%+21.5%$782.70MN/A-18.5440Earnings ReportAnalyst ForecastNews CoverageGap UpKROSKeros Therapeutics3.3774 of 5 stars$19.31+2.5%$81.33+321.2%-56.3%$782.19M$651,000.00-3.61100Analyst ForecastHigh Trading VolumeKURAKura Oncology4.4825 of 5 stars$9.96+3.4%$29.38+194.9%-35.3%$774.49MN/A-4.08142IMNMImmunome2.7301 of 5 stars$12.32-2.1%$28.83+134.0%+17.4%$768.98M$10.13M-1.5540Positive NewsTYRATyra Biosciences2.129 of 5 stars$15.06+0.8%$31.00+105.8%+4.8%$762.04MN/A-9.2820ERASErasca2.064 of 5 stars$2.62+2.3%$5.90+125.2%+21.8%$740.75MN/A-3.08126 Related Companies and Tools Related Companies uniQure Alternatives 89bio Alternatives Pliant Therapeutics Alternatives Relay Therapeutics Alternatives Anavex Life Sciences Alternatives Keros Therapeutics Alternatives Kura Oncology Alternatives Immunome Alternatives Tyra Biosciences Alternatives Erasca Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INBX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INBX Stock Alerts